Abraham Susan C, Wu Tsung-Teh, Hruban Ralph H, Lee Jae-Hyuk, Yeo Charles J, Conlon Kevin, Brennan Murray, Cameron John L, Klimstra David S
Department of Pathology, Division of GI/LiverPathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196, USA.
Am J Pathol. 2002 Mar;160(3):953-62. doi: 10.1016/s0002-9440(10)64917-6.
Acinar cell carcinomas (ACCs) are rare malignant tumors of the exocrine pancreas. The specific molecular alterations that characterize ACCs have not yet been elucidated. ACCs are morphologically and genetically distinct from the more common pancreatic ductal adenocarcinomas. Instead, the morphological, immunohistochemical, and clinical features of ACCs overlap with those of another rare pancreatic neoplasm, pancreatoblastoma. We have recently demonstrated a high frequency of allelic loss on chromosome arm 11p and mutations in the APC/beta-catenin pathway in pancreatoblastomas, suggesting that similar alterations might also play a role in the pathogenesis of some ACCs. We analyzed a series of 21 ACCs for somatic alterations in the APC/beta-catenin pathway and for allelic loss on chromosome 11p. In addition, we evaluated the ACCs for alterations in p53 and Dpc4 expression using immunohistochemistry, and for microsatellite instability (MSI) using polymerase chain amplification of a panel of microsatellite markers. Allelic loss on chromosome 11p was the most common genetic alteration in ACCs, present in 50% (6 of 12 informative cases). Molecular alterations in the APC/beta-catenin pathway were detected in 23.5% (4 of 17) of the carcinomas, including one ACC with an activating mutation of the beta-catenin oncogene and three ACCs with truncating APC mutations. One ACC (1 of 13, 7.6%) showed allelic shifts in four of the five markers tested (MSI-high), two (15.4%) showed an allelic shift in only one of the five markers tested (MSI-low), and no shifts were detected in the remaining 10 cases. The MSI-high ACC showed medullary histological features. In contrast, no loss of Dpc4 protein expression or p53 accumulation was detected. These results indicate that ACCs are genetically distinct from pancreatic ductal adenocarcinomas, but some cases contain genetic alterations common to histologically similar pancreatoblastomas.
腺泡细胞癌(ACCs)是胰腺外分泌腺的罕见恶性肿瘤。目前尚未阐明其特征性的特定分子改变。ACCs在形态学和遗传学上与更常见的胰腺导管腺癌不同。相反,ACCs的形态学、免疫组化和临床特征与另一种罕见的胰腺肿瘤——胰腺母细胞瘤有重叠。我们最近证明胰腺母细胞瘤中11号染色体短臂上等位基因缺失的频率很高,且APC/β-连环蛋白途径存在突变,这表明类似的改变可能在某些ACCs的发病机制中也起作用。我们分析了21例ACCs,检测其APC/β-连环蛋白途径的体细胞改变以及11号染色体短臂上的等位基因缺失情况。此外,我们采用免疫组化评估ACCs中p53和Dpc4表达的改变,并使用一组微卫星标记进行聚合酶链反应扩增来检测微卫星不稳定性(MSI)。11号染色体短臂上的等位基因缺失是ACCs中最常见的基因改变,在50%(12例信息充分的病例中有6例)的病例中出现。在23.5%(17例中有4例)的癌中检测到APC/β-连环蛋白途径的分子改变,包括1例具有β-连环蛋白癌基因激活突变的ACC和3例具有APC截短突变的ACC。1例ACC(13例中有1例,7.6%)在检测的5个标记中有4个出现等位基因移位(高微卫星不稳定性),2例(15.4%)仅在检测的5个标记中的1个出现等位基因移位(低微卫星不稳定性),其余10例未检测到移位。高微卫星不稳定性的ACC表现出髓样组织学特征。相反,未检测到Dpc4蛋白表达缺失或p53积聚。这些结果表明,ACCs在遗传学上与胰腺导管腺癌不同,但某些病例含有与组织学上相似的胰腺母细胞瘤共有的基因改变。
Oncogene. 2002-11-14
World J Surg Oncol. 2025-1-29
Cancers (Basel). 2024-10-9
NPJ Precis Oncol. 2024-10-3
J Cancer Res Clin Oncol. 2024-7-11
J Cancer Metastasis Treat. 2023
Int J Cancer. 2000-12-1
Ultrastruct Pathol. 2000
J Clin Gastroenterol. 2000-9